• Home | Global Data CRO
  • Our Company
    • About Us
    • Executive Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Leaders
    • Working with MMS
    • Certifications
  • Services
    • Regulatory Affairs
      • Regulatory Affairs Services
      • Regulatory Strategy Consulting
      • Regulatory Affairs Management
      • Regulatory Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Transparency Services
      • Transparency and Disclosure Services
      • REGISTRATION AND RESULTS DISCLOSURES
      • Data and Document Anonymization
      • LAY SUMMARIES
    • Quality and Compliance services
    • Drug Safety and Pharmacovigilance
    • Rare Disease
    • Quality Control Services
    • Project Advisory Services
    • Data Science
  • Technology
    • Datacise
    • Automatiqc
    • PVantage
    • Technology Implementation
    • SmartStart Document Templates
  • Functional Services (FSP)
  • Webinars
  • News and Media
  • MMS Blog
  • Careers
    • MMS Careers
    • Opportunities
    • MMS Experience
    • MMS Culture
    • Global Benefits
    • FAQ
  • Learning
  • Contact Us
MMS Holdings
Natural Language Processing in Healthcare: The Pros, Cons, and Potential Impact

Natural Language Processing in Healthcare: The Pros, Cons, and Potential Impact

by Avery Zimmerman | Aug 16, 2022 | Blog

Natural language processing (NLP) is a powerful tool revolutionizing how information is collected, stored and used in healthcare and health science. Due to the complexity of data in a healthcare setting, natural language processing is a particularly useful data...
Attending the 2022 PHUSE US Connect: A Data Scientist’s Experience

Attending the 2022 PHUSE US Connect: A Data Scientist’s Experience

by Avery Zimmerman | May 31, 2022 | Blog

Attending the 2022 PHUSE US Connect in Atlanta was similar to attending a concert for one of your favorite music artists. Technology does a fantastic job trying to virtually mimic in-person interaction, whether it’s a virtual meeting with your peers or watching a...
MMS Holdings To Debut Datacise Integrated Safety Explorer To Detect Safety Signals

MMS Holdings To Debut Datacise Integrated Safety Explorer To Detect Safety Signals

by Avery Zimmerman | Mar 4, 2020 | News

MMS Holdings to Debut Datacise Integrated Safety Explorer to Detect Safety Signals Using Real-World Evidence During PHUSE/FDA Data Science Innovation Challenge CANTON, Mich. (March 4, 2020) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today...
Recommended Reading from Eight Pharmaceutical Experts This Summer

Recommended Reading from Eight Pharmaceutical Experts This Summer

by Avery Zimmerman | Aug 15, 2019 | Blog

Summer reading isn’t reserved for school-aged children, as adults and professionals alike can gain knowledge and insights from consistently reading material during the hottest months of the year. With Book Lover’s Day last week, we asked eight colleagues from varying...
Building a robust clinical data science process

Building a robust clinical data science process

by curtis@digitalliance.com | Jun 7, 2018 | Blog

During PhUSE US Connect 2018 – the clinical data science conference – in Raleigh, North Carolina, MMS data science experts presented a paper and corresponding poster, titled Big Data Paradox: Development of a Unique and Repeatable Analytical Process while Implementing...

Recent Posts

  • Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth
  • What is FDA’s Project Renewal? The Modernization of Decades Old Oncology Drug Labels
  • FDA Updates IND Expanded Access Guidance for Industry
  • What is Regulatory Information Management System (RIMS)?
  • Expanded Access to IND – Full Question and Answer in Draft Guidance

Tags

biostatistics Careers clinical research clinical study reports clinical trial disclosure clinical trials clinical trial transparency Compliance conference COVID-19 CRO data management data privacy data science decentralized clinical trials diversity and inclusion drug development eCOA & ePro EMA FDA Functional Service Provider (FSP) GXP auditing Health Analytics Collective innovation Lay summaries leadership medical writing MMS Academy NDA submission News Orphan Drug Designation Applications PDUFA VII pharmacovigilance PhUSE plain language summary Policy 0070 Praxis bioresearch quality and compliance quality control rare disease real world data regulatory affairs regulatory operations statistical programming transparency